Therapies in development for castrate-resistant prostate cancer

Andrea L. Harzstark, Charles J. Ryan

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


The paucity of active medical therapies for advanced prostate cancer underlies a critical need for clinical research in this area. Multiple new treatments are being evaluated, including therapies that target adrenal androgens, such as abiraterone; new chemotherapies, such as the oral platinum analog, satraplatin, and an epothilone analog, ixabepilone; combinations of chemotherapy with other agents, such as the VEGF inhibitor, bevacizumab, and calcitriol; as well as multiple immunotherapeutics, including sipuleucel-T, GVAX and ipilimumab. This review will highlight the promise of these new approaches and the challenges to their development.

Original languageEnglish (US)
Pages (from-to)259-268
Number of pages10
JournalExpert Review of Anticancer Therapy
Issue number2
StatePublished - Feb 2008
Externally publishedYes


  • Abiraterone
  • Adrenal androgens
  • Atrasentan
  • Bevacizumab
  • Calcitriol
  • Castrate-resistant prostate cancer
  • Chemotherapy
  • GVAX
  • Immunotherapy
  • Ipilimumab
  • Ixabepilone
  • Phase II
  • Satraplatin
  • Sipuleucel-T


Dive into the research topics of 'Therapies in development for castrate-resistant prostate cancer'. Together they form a unique fingerprint.

Cite this